Search

Displaying results 2121 - 2130 of 4438 in total
  1. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader. It was identified through a targeted medicinal chemistry optimization campaign to act as...

  2. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    It is administered by the intravenous, epidural and sublingual routes. … The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717].

  3. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.

  4. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985).

  5. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].

  6. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    clots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood

  7. Drug

    Ammonia

    go.drugbank.com/drugs/DB11118
    ApprovedInvestigational

    of protein by the Krebs-Hanseleit cycle in the liver [L2033]. … It is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis

  8. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.

    Products: (Alglucosidase alfa) 50mg Powder for Solution for Infusion
  9. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent. [PubChem]

  10. Drug

    Aluminum sulfate

    go.drugbank.com/drugs/DB11239
    Approved

    By overcoming the body barriers, Al may infiltrate into the blood and lead to toxic effects in liver, bone and the central nervous system [L2145].